CSIMarket
 
Amneal Pharmaceuticals Inc   (NASDAQ: AMRX)
 
Price: $17.4400 $-0.43 -2.406%
Day's High: $17.704999923706055 Week Perf: -0.17 %
Day's Low: $ 17.38 30 Day Perf: -3.49 %
Volume (M): 1,426,045 52 Wk High: $ 19.26
Volume (M$): $ 0 52 Wk Avg: $13.56
Open: $17.57 52 Wk Low: $9.49



 Market Capitalization (Millions $) 5,722
 Shares Outstanding (Millions) 328
 Employees 8,500
 Revenues (TTM) (Millions $) 3,117
 Net Income (TTM) (Millions $) 215
 Cash Flow (TTM) (Millions $) 121
 Capital Exp. (TTM) (Millions $) 168

Business Description


Amneal Pharmaceuticals Inc. is a global pharmaceutical company that specializes in the development, manufacture, and distribution of high-quality generic and branded pharmaceutical products. The company was founded in 2005 by Chirag and Chintu Patel, and is headquartered in Bridgewater, New Jersey, United States.

Amneal has a broad portfolio of products that spans across various therapeutic areas, including CNS disorders, gastrointestinal disorders, cardiovascular diseases, and pain management. The company's products are distributed in more than 150 countries worldwide, through a combination of direct sales, strategic partnerships, and licensing agreements.

Amneal Pharmaceuticals has several manufacturing facilities that operate under strict quality control guidelines and adhere to international regulatory standards. The company's manufacturing facilities are located in the United States, India, Germany, the United Kingdom, and Ireland.

The company has a strong research and development (R&D) pipeline that focuses on developing novel pharmaceutical products using innovative delivery technologies. The R&D team consists of experienced scientists and researchers who work in state-of-the-art laboratories and collaborate with academic institutions and other pharmaceutical companies to develop new and innovative products.

Amneal Pharmaceuticals has received numerous awards and recognitions for its contribution to the pharmaceutical industry. In 2020, the company was named "Generics Company of the Year" by the Generic Pharmaceutical Association (GPhA) and ranked #331 in the Fortune 500 list.

The company's mission is to improve patient health by providing high-quality, affordable pharmaceutical products to people around the world. The company is committed to sustainability and ethical business practices, and has a strong corporate social responsibility program that supports community development, education, and environmental conservation initiatives.

In summary, Amneal Pharmaceuticals Inc. is a global pharmaceutical company that specializes in the development, manufacture, and distribution of high-quality generic and branded pharmaceutical products. The company has a broad portfolio of products that are distributed in more than 150 countries worldwide, and has a strong research and development pipeline that focuses on developing innovative pharmaceutical products. The company is committed to sustainability and ethical business practices, and has a strong corporate social responsibility program.


   Company Address: 400 Crossing Boulevard, Bridgewater 8807 NJ
   Company Phone Number: 947-3120   Stock Exchange / Ticker: NASDAQ AMRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALKS   -2.76%    
ANIP   -2.2%    
PFE        1.75% 
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   



Partnership

Amneal Pharmaceuticals Innovating Through Collaboration Amidst Market Fluctuations,

Published Thu, May 8 2025 12:18 PM UTC

Amneal Pharmaceuticals Expands to Meet Rising Demand in U.S. Pharmaceutical Manufacturing In a strategic move to bolster its capabilities in advanced pharmaceutical manufacturing, Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) has entered into a partnership with Apiject to expand its sterile and Blow-Fill-Seal (BFS) manufacturing operations. This collaboration aims to enhance t...

Business Update

Navigating Innovation Amneal Pharmaceuticals’ Collaborative and Approvals Pathway,

Published Tue, Oct 1 2024 12:47 PM UTC

Amneal Pharmaceuticals Strategic Moves in the Biopharmaceutical Arena: A Focus on Innovation and Collaboration Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), a reputed name in the global pharmaceutical industry, has embarked on strategic initiatives aimed at advancing medical treatments and addressing critical therapeutic areas. The recent collaboration with Metsera, Inc. and...

Business Update

Approval of BORUZU The First Ready-to-Use Bortezomib for Enhanced Oncology Care,

Published Fri, Sep 6 2024 5:09 AM UTC

Approval of BORUZU: A Game-Changer in Bortezomib Administration Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited have jointly announced the U.S. Food and Drug Administration (FDA) approval of BORUZU, marking a significant advancement in the treatment landscape for patients requiring bortezomib therapy. BORUZU is noted as the first ready-to-use formulation of bortezom...

Business Update

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU The First Ready-to-Use Bortezomib Injection for Subcutaneous A...

Published Thu, Sep 5 2024 9:09 PM UTC

Amneal and Shilpa Secure U.S. FDA Approval for BORUZU: A Ready-to-Use Bortezomib Injection for Subcutaneous Administration Bridgewater, N.J. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (Amneal) and Shilpa Medicare Limited (Shilpa) today announced that the U.S. Food and Drug Administration (FDA) has approved BORUZU, marking the debut of a revolutionary ready-to-use versio...

Business Update

Unveiling Innovation Amneal Pharmaceuticals Earns FDA Approval for Propofol Injectable Emulsion Single-Do...

Published Tue, Aug 20 2024 12:47 PM UTC

BRIDGEWATER, N.J. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) has achieved a significant milestone that promises to enhance clinical practices in the administration of anesthesia. The U.S. Food and Drug Administration (FDA) has granted Abbreviated New Drug Application (ANDA) approval for Amneal s Propofol Injectable Emulsion USP, available in three concentrations: 200 m...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 35.59
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.84
Price to Sales (Expected) -
Price to Book 173.27
PEG (TTM) 0.01

Financial Strength Current
Quick Ratio 0.15
Working Capital Ratio 2.2
Leverage Ratio (MRQ) 115.89
Total Debt to Equity 78.01
Interest Coverage (TTM) 3.41
Debt Coverage (TTM) 0.16

Per Share Current
Earnings (TTM) 0.49 $
Revenues (TTM) 9.5 $
Cash Flow (TTM) 0.37 $
Cash 0.42 $
Book Value 0.1 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 366,762
Net Income per Employee (TTM) 25,332
Receivable Turnover Ratio (TTM) 13.9
Inventory Turnover Ratio (TTM) 2.98
Asset Turnover Ratio (TTM) 0.85

Profitability Ratios Current
Gross Margin (MRQ) 42.01 %
Operating Margin (MRQ) 16.3 %
Net Margin (MRQ) 8.74 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 5.9 %
Return On Investment (TTM) 7.91 %
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Amneal Pharmaceuticals Inc's Segments
Affordable Medicines    114.69 % of total Revenue
Specialty    35.49 % of total Revenue
AvKARE    40.57 % of total Revenue
Amneal Specialty Pharma    35.49 % of total Revenue

  Amneal Pharmaceuticals Inc Outlook

On August 12 2024 the Amneal Pharmaceuticals Inc provided following guidance

nnAmneal Pharmaceuticals Inc. Raises Full-Year 2024 Guidance Following Robust Q2 Resultsnn

On August 12, 2024, Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) unveiled its financial results for the second quarter ending June 30, 2024. The company reported a significant increase in revenues and adjusted EBITDA, reflecting its ongoing commitment to growth and operational excellence across various segments of its business.

In response to this strong performance, Amneal has announced an upward revision of its full-year guidance for 2024. The decision to adjust the guidance is indicative of substantial growth experienced across the company's portfolio, although specific numerical metrics were not di...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.